EU extends corona entry freeze to Japan – decision on opening schools and daycare centers in the southwest postponed

The British Prime Minister Boris Johnson announces the government will decide on stricter border rules to contain the corona pandemic on Wednesday. The interior minister will take tougher measures for countries that are on the red list because of the spread of the corona mutations, says Johnson in parliament. Permanent border closings are not a solution. In the UK, the number of people who died from COVID 19 has risen to over 100,000.

Opposition leader Keir Starmer accused the British Prime Minister of not having learned from his mistakes in the pandemic. “The problem is that the important lessons have not been learned,” Starmer said during the traditional questioning of the Prime Minister in the London House of Commons. “Why does the UK have the highest death toll in Europe? Why does Britain have almost the highest death rate in the world? “asked the head of the Labor Party. Whether testing, imposing lockdowns or the rules for Christmas – Boris Johnson hesitated too long about everything and made important decisions too late.

Johnson defended himself with reference to the particularly contagious corona variant B.1.1.7 discovered in Great Britain, which had made the fight against the pandemic even more difficult.

.

Decision on opening schools and daycare centers in the southwest postponed – Prime Minister Johnson announces stricter border rules

The British Prime Minister Boris Johnson announces the government will decide on stricter border rules to contain the corona pandemic on Wednesday. The interior minister will take tougher measures for countries that are on the red list because of the spread of the corona mutations, says Johnson in parliament. Permanent border closings are not a solution. In the UK, the number of people who died from COVID 19 has risen to over 100,000.

Opposition leader Keir Starmer therefore accused the British Prime Minister of not having learned from his mistakes in the pandemic. “The problem is that the important lessons have not been learned,” Starmer said during the traditional questioning of the prime minister in the London House of Commons. “Why does the UK have the highest death toll in Europe? Why does Britain have almost the highest death rate in the world?asked the head of the Labor Party. Whether it’s testing, imposing lockdowns or the rules for Christmas – Boris Johnson hesitated too long about everything and made important decisions too late.

Johnson defended himself with reference to the particularly contagious corona variant B.1.1.7 discovered in Great Britain, which had made the fight against the pandemic even more difficult.

.

Margarita Robles asks Jemad for a report of explanations after learning that she has received the first dose of the vaccine

Friday, 22 January 2021 – 20:36

The Armed Forces have their own vaccine quota that does not include the personnel of the Gmez Ulla Defense Hospital

Margarita Robles asks Jemad for a report of explanations for having been vaccinated
THE WORLD

He Ministry of Defence has put hands on the wall. Its owner, Margarita Robles, has ordered an urgent clarification from the Chief of the Defense Staff, General Miguel ngel Villarroya, after learning from the press that, along with other military commanders, he has already received the coronavirus vaccine.

The minister, after an act that pays tribute to the military who have participated in the fight against FilomenaHe has not hidden his discomfort at learning of the vaccination of his right hand in the armies and other members of the military leadership and has assured that he has requested a report from General Villarroya that he hopes to have on his table this afternoon.

The minister wants to know all the details of why this command has been vaccinated, if appropriate according to the Defense plans and who else has been vaccinated. You want an accurate report with all the details. Robles is no stranger to the discomfort that the vaccinations that have occurred in the political sphere have generated in the citizenry, skipping the waiting list.

According to Defense sources, the minister hopes that the explanations and data that are put on the table contain a solid argument about the reasons that have led to this vaccination.

The protocol of the Armed Forces

Robles has requested a report to know in detail the protocol that has been followed to establish vaccination priorities within Jemad. From military sources they explain that the Armed Forces have an agreed quota of vaccines with Health and that they have an established protocol to vaccinate.

The priority: its medical personnel, the troops traveling on international missions, and then the chain of command. This fee does not include the staff of the Gmez Ulla Defense Hospital in Madrid, where vaccination was suspended as well as the rest of the health Community.

“I have asked General Villarroya for a report and depending on what the report says, we will see,” declared the minister, visibly upset with the situation. Yes, he made it clear that the Jemad always works “very rigorously”.

“I cannot make any decision because I do not know how the vaccination plan is developing until the Jemad gives me the corresponding information,” he explained.

Other military vaccinated

What Robles has confirmed is that within the Ministry of Defence “No one is vaccinated”, since the criteria established by the Ministry of Health have been followed: “Residences, health personnel and then strategic personnel”, according to reports Europa Press.

Among the names that are considered for those vaccinated, in addition to General Villarroya, would be the Chief of the Joint Chiefs of Staff (Jemacon), Lieutenant General Fernando Garca Gonzlez-Valerio, the Commander of the Operations Command (CMOPS), Lieutenant General Francisco Braco Carb and the Support Deputy of the Chief of Staff of the Operations Command, Brigadier General Carlos Prada Larrea. The vaccination was carried out following an age criterion.

According to the criteria of

The Trust Project

Know more

.

+++ Corona-News +++: Seehofer checks restriction of air traffic “to almost zero” – Sanofi helps Biontech with vaccine production

+++ Netherlands expect another riot night +++ Two percent of Germans are vaccinated +++ Bavarian administrative judges overturn the 15-kilometer rule +++ The news blog. .

Honduras’s trade deficit decreased by 28.1% in eleven months of 2020

Tegucigalpa.

He trade deficit The Honduran figure for the first eleven months of 2020 stood at 3,877.8 million dollars, 28.1% less than in the same period of 2019 (5,395.4 million), the Central Bank of the country (BCH) reported on Tuesday.

The entity indicated that the contraction is mainly justified by the “fall in national economic activity as a result of the pandemic of the covid-19, which in turn reduced imports of goods. “

Despite the adverse effects of the global health crisis and the damage left by tropical storms Eta and Iota, last November, merchandise exports increased by 1.3% between January and November 2020, to 3,849.7 million dollars, compared to 3,800.3 million in the same period of 2019, he added.

The rise in exports is due to the increase in sales of bananas, palm oil, gold and cigars (tobacco), said the central bank.

Imports, for their part, fell 16% and stood at 7,727.4 million dollars, compared to 9,195.7 million in the same period of 2019.

The decrease in imports It is the result of fewer purchases of raw materials, capital goods and intermediaries, and inputs, added the Honduran entity.

The Central Bank pointed out that the United States was the main trading partner of Honduras in the first eleven months of 2020, since that market generated 1,416.2 million dollars, followed by Latin America with 1,066.6 million.

It is followed in third place by Europe with 1,034.1 million dollars, Central America with 844.4 million dollars and in fifth place the rest of the world with 219.5 million, said the Honduran organization.

The main suppliers to Honduras are the United States, Central America, Europe and some Latin American countries.

The main product of Honduras’s export is coffee, a country that in the 2019-2020 harvest sold 7.2 million bags and received 900 million dollars.

In the 2020-2021 harvest, the country expects to harvest a little more than 8.9 million bags of coffee, of which 750,000 are destined for domestic consumption in the country and the remaining 8.2 million are exported.

Honduras, the largest aromatic producer in Central America, sold some 61 million dollars in the first two months of the 2020-2021 harvest, compared to 101 million in the previous period, and exported 471,000 quintals of the grain (46 kilos), according to the Honduran Coffee Institute (Ihcafe).

.

Smokers are more likely to die from COVID-19

/ Nopphon, stockadobecom

Cleveland / Ohio – Long-term smokers are more likely to develop COVID-19 seriously if they are infected with SARS-CoV-2. According to an analysis of a patient registry, they are in JAMA Internal Medicine (2021; DOI: 10.1001 / jamainternmed.2020.8360) more often in the hospital and treated there in the intensive care unit. The risk of death was also increased.

Long-term smoking not only damages the lungs, it also leads to accelerated atherosclerosis, which leads to arterial hypertension and cardiovascular diseases. It was therefore surprising that tobacco smoking could not be identified as a clear risk factor for a severe course of COVID-19 in previous studies, although SARS-CoV-2 infects the endothelium of the blood vessels in addition to the lungs.

One reason could be inaccurate information in the medical records. The patients are often only asked about their current habits. When smoking, however, the cumulative dose is decisive, which can best be determined by specifying the year of the pack. This is the number of packs smoked daily multiplied by the number of years you smoke. This information was recorded in the patient registry that the Cleveland Clinic set up in March last year for COVID-19.

So far, data has been collected on 7,102 patients, of whom 172 were active and 910 were former smokers. A total of 341 had more than 30 pack years. The hospitalization rate in this group was 4.65 times higher than in the never-smokers. They were treated 2.11 times more often in intensive care and their risk of death was 6.2 times higher.

Most of the risk could be traced back to the significantly older age of long-term smokers. But even when age, gender and ethnic origin were taken into account, more than 30 pack years with an increased risk of hospitalization (odds ratio 2.25; 95% confidence interval 1.76 to 2.88), treatment in the intensive care unit ( Odds ratio 1.69; 1.23 to 2.35) and one death (odds ratio 1.89; 1.29 to 2.76) were significant.

Further analyzes showed that the risk is mainly due to the accompanying illnesses. 30 packaging years leave their mark on the body: 85.5% had arterial hypertension at an average age of 71, 47.2% had COPD or emphysema, 43.1% had coronary heart disease, 32.3% had cardiac insufficiency, 30, 8% cancer (current or history) and 22.9% asthma. Long-term smoking is life-threatening even without SARS-CoV-2 and can hardly be reconciled with healthy aging. © rme / aerzteblatt.de

.

The secret of the centenarians who defeated the coronavirus

SEEN FROM ELSEWHERE – They are more resilient than young people to the virus, and many of them had to fight the Spanish flu first. Explanations from an immunologist.

By Elena Dusi (The Republic)

They have just crushed the coronavirus under the weight of their 107 years. A lady from Caorle was declared cured on New Year’s Eve. Around the same time as another lady of the same age from Loro Piceno. But these are not the oldest citizens to have survived the coronavirus: last September and June, respectively, a 108-year-old man from Genoa and a woman of the same age from Milan also managed to knock out the virus. record, however, goes to the Spaniard Maria Branyas, born in 1907 and resident of a Catalan retirement home. The latter was probably infected during the party organized for her 113th birthday, but only developed a few mild symptoms.

Many cured centenarians remember beating the Spanish flu a century ago. ” What if it was the result of residual immunity? Claudio Franceschi, a professor, wonders

This article is for subscribers only. You have 89% left to discover.

Subscribe: 1 € the first month

Can be canceled at any time

Already subscribed? Log in

.

Effective therapy with combined antibody active ingredients – healing practice

Combined antibody active ingredients effective against COVID-19

Effective treatment options for COVID-19 have been urgently sought after the outbreak of the pandemic. The use of special neutralizing antibodies against the SARS-CoV-2 coronavirus appears to be a promising option. Bamlanivimab is an example of such an antibody drug.

To what extent treatment with bamlanivimab or a combined therapy with bamlanivimab and etesevimab (also an antibody agent) can be helpful in COVID-19, the research team led by Dr. Robert L. Gottlieb from Baylor University Medical Center and Baylor Scott and White Research Institute (USA) investigated in a recent study. The results were published in the specialist magazine “JAMA”.

Various treatments tested

A total of 577 patients with mild or moderate disease of COVID-19 received either a single infusion of bamlanivimab (700 mg 101 people; 2800 mg 107 people; 7000 mg 101 people), a combination treatment with bamlanivimab and etesevimab (each 2800 mg in 112 people]) or a placebo (156 people).

Decreased viral load after eleven days

The research team then examined whether the treatment had an impact on factors such as viral load, the symptoms occurring, required hospital stays or the risk of fatal disease courses. For example, in a control measurement eleven days after treatment, the viral load was significantly lower when the participants received a combination therapy of bamlanivimab and etesevimab. Treatment with bamlanivimab alone had no effect here.

Deviation from previous results

“Treatment with the combination therapy of bamlanivimab and etesevimab, but not bamlanivimab monotherapy, resulted in a reduction in the SARS-CoV-2 log viral load on day 11 in patients with mild to moderate COVID-19,” reports the research team. Accordingly, early treatment with the antibody active ingredients could have positive effects in the moderate forms of COVID-19.

In an editorial article by the specialist magazine “JAMA” on the current study results, it is pointed out that in an earlier publication from the same study, treatment with a 2800 mg dose of bamlanivimab alone also significantly reduced the viral load compared to placebo, while the 700 mg and 7000 mg doses did not.

The different results are presumably due to the fact that at the time of the earlier publication the follow-up for the placebo group was still incomplete. “The comparison of the monotherapy groups with the final results for the placebo group led to changes in the effect sizes and to a loss of previously reported statistical significance in the group that received 2,800 mg bamlanivimab,” reports the specialist journal.

Limited significance of the viral load

The editorial article also points out that although an objective and measurable primary endpoint was used with the viral load after eleven days, this endpoint is not necessarily clinically meaningful. Because “the viral load naturally decreases in the course of the disease, and statistically significant differences in this endpoint can only occur if treatment is given early in the course of the disease.”

Consider required hospital stays

Therefore, the predefined secondary endpoints such as COVID-19-related hospital stays, required treatments in the intensive care unit and deaths are more meaningful here. In the current study, for example, the proportion of participants with COVID-19-related hospital stays or visits to the emergency room was 5.8 percent in the placebo group. When treated with 700 mg bamlanivimab, this decreased to 1 percent (2,800 mg bamlanivimab 1.9 percent and 7000 mg bamlanivimab 2 percent) and with combination therapy to 0.9 percent.

Overall, the results therefore speak in favor of a positive effect of the antibody active ingredients, which must now be examined in further studies. (fp)

Author and source information

This text complies with the requirements of specialist medical literature, medical guidelines and current studies and has been checked by medical professionals.

Author:

Dipl. Geogr. Fabian Peters

Swell:

  • Robert L. Gottlieb, Ajay Nirula, Peter Chen, Joseph Boscia, Barry Heller, Jason Morris, Gregory Huhn, Jose Cardona, Bharat Mocherla, Valentina Stosor, Imad Shawa, Princy Kumar, Andrew C. Adams, Jacob Van Naarden, Kenneth L. Custer, Michael Durante, Gerard Oakley, Andrew E. Schade, Timothy R. Holzer, Philip J. Ebert, Richard E. Higgs, Nicole L. Kallewaard, Janelle Sabo, Dipak R. Patel, Paul Klekotka, Lei Shen, Daniel M. Skovronsky: Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19; in: JAMA (veröffentlicht 21.01.2021), jamanetwork.com
  • Preeti N. Malani, Robert M. Golub: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19; in: JAMA (veröffentlicht 21.01.2021), jamanetwork.com

Important NOTE:
This article is for general guidance only and is not intended to be used for self-diagnosis or self-treatment. He can not substitute a visit at the doctor.

.

Effective therapy with combined antibody active ingredients – healing practice

Combined antibody active ingredients effective against COVID-19

Effective treatment options for COVID-19 have been urgently sought after the outbreak of the pandemic. The use of special neutralizing antibodies against the SARS-CoV-2 coronavirus appears to be a promising option. Bamlanivimab is an example of such an antibody drug.

To what extent treatment with bamlanivimab or a combined therapy with bamlanivimab and etesevimab (also an antibody agent) can be helpful in COVID-19, the research team led by Dr. Robert L. Gottlieb from Baylor University Medical Center and Baylor Scott and White Research Institute (USA) investigated in a recent study. The results were published in the specialist magazine “JAMA”.

Various treatments tested

A total of 577 patients with mild or moderate disease of COVID-19 received either a single infusion of bamlanivimab (700 mg 101 people; 2800 mg 107 people; 7000 mg 101 people), a combination treatment with bamlanivimab and etesevimab (each 2800 mg in 112 people]) or a placebo (156 people).

Decreased viral load after eleven days

The research team then examined whether the treatment had an impact on factors such as viral load, the symptoms occurring, required hospital stays or the risk of fatal disease courses. For example, in a control measurement eleven days after treatment, the viral load was significantly lower when the participants received a combination therapy of bamlanivimab and etesevimab. Treatment with bamlanivimab alone had no effect here.

Deviation from previous results

“Treatment with the combination therapy of bamlanivimab and etesevimab, but not bamlanivimab monotherapy, resulted in a reduction in the SARS-CoV-2 log viral load on day 11 in patients with mild to moderate COVID-19,” reports the research team. Accordingly, early treatment with the antibody active ingredients could have positive effects in the moderate forms of COVID-19.

In an editorial article by the specialist magazine “JAMA” on the current study results, it is pointed out that in an earlier publication from the same study, treatment with a 2800 mg dose of bamlanivimab alone also significantly reduced the viral load compared to placebo, while the 700 mg and 7000 mg doses did not.

The different results are presumably due to the fact that at the time of the earlier publication the follow-up for the placebo group was still incomplete. “The comparison of the monotherapy groups with the final results for the placebo group led to changes in the effect sizes and to a loss of previously reported statistical significance in the group that received 2,800 mg bamlanivimab,” reports the specialist journal.

Limited significance of the viral load

The editorial article also points out that although an objective and measurable primary endpoint was used with the viral load after eleven days, this endpoint is not necessarily clinically meaningful. Because “the viral load naturally decreases in the course of the disease, and statistically significant differences in this endpoint can only occur if treatment is given early in the course of the disease.”

Consider required hospital stays

Therefore, the predefined secondary endpoints such as COVID-19-related hospital stays, required treatments in the intensive care unit and deaths are more meaningful here. In the current study, for example, the proportion of participants with COVID-19-related hospital stays or visits to the emergency room was 5.8 percent in the placebo group. When treated with 700 mg bamlanivimab, this decreased to 1 percent (2,800 mg bamlanivimab 1.9 percent and 7000 mg bamlanivimab 2 percent) and with combination therapy to 0.9 percent.

Overall, the results therefore speak in favor of a positive effect of the antibody active ingredients, which must now be examined in further studies. (fp)

Author and source information

This text complies with the requirements of specialist medical literature, medical guidelines and current studies and has been checked by medical professionals.

Author:

Dipl. Geogr. Fabian Peters

Swell:

  • Robert L. Gottlieb, Ajay Nirula, Peter Chen, Joseph Boscia, Barry Heller, Jason Morris, Gregory Huhn, Jose Cardona, Bharat Mocherla, Valentina Stosor, Imad Shawa, Princy Kumar, Andrew C. Adams, Jacob Van Naarden, Kenneth L. Custer, Michael Durante, Gerard Oakley, Andrew E. Schade, Timothy R. Holzer, Philip J. Ebert, Richard E. Higgs, Nicole L. Kallewaard, Janelle Sabo, Dipak R. Patel, Paul Klekotka, Lei Shen, Daniel M. Skovronsky: Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19; in: JAMA (veröffentlicht 21.01.2021), jamanetwork.com
  • Preeti N. Malani, Robert M. Golub: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19; in: JAMA (veröffentlicht 21.01.2021), jamanetwork.com

Important NOTE:
This article is for general guidance only and is not intended to be used for self-diagnosis or self-treatment. He can not substitute a visit at the doctor.

.

Increased risk of severe disease progression in rheumatoid patients

First evaluation of rheumatism and COVID-19

Are rheumatism patients exposed to higher risks than healthy people with a SARS-CoV-2 infection? Do rheumatoid drugs affect the course of COVID-19? A German research team investigated these questions and evaluated data from rheumatism sufferers who fell ill with COVID-19.

Researchers from the German Society for Rheumatology eV (DGRh) and the University of Gießen analyzed data from the online register “Covid19-rheuma.de”. Since the beginning of the coronavirus pandemic, cases of rheumatism sufferers who have contracted COVID-19 have been collected in the register. The evaluation of the register data has now been published in the specialist journal “RMD Open”.

Basic rheumatic disease as a COVID-19 risk factor

The data analysis is intended to serve as a basis for assessing the risk of the connection between underlying rheumatic diseases and severe courses of COVID-19. “Inflammatory rheumatic diseases represent a permanent burden on the patient’s immune system,” explains the working group in a press release on the evaluation. The immune activity that is typical of the disease and directed against the body’s own tissue binds the capacities of the immune system and can lead to an increased susceptibility to infection, especially if the disease is active and not treated.

Rheumatism drugs reduce the immune system

“On the other hand, the drugs that are used for rheumatism therapy can also reduce the immune system,” adds Professor Dr. med. Hendrik Schulze-Koops added. He is President of the DGRh and head of the rheumatism unit at the University Hospital of the Ludwig Maximilians University in Munich. At the beginning of the corona pandemic, there was therefore great uncertainty among those affected by rheumatism as well as among medical professionals. The aim of the registry was therefore to investigate these uncertainties in order to be able to make an evidence-based recommendation.

Data from 468 rheumatism sufferers evaluated

468 rheumatism sufferers who contracted COVID-19 were monitored via the register. “Of the total of 468 registered patients, 136 had to be hospitalized, 26 needed ventilation,” summarizes the corresponding study author Dr. med. Anne C. Regierer from the German Rheumatism Research Center Berlin (DRFZ).

General risk factors of COVID-19

The evaluation showed that the known risk factors for severe COVID-19 courses in the general population are also reflected in rheumatism sufferers. Over 65-year-olds had a 2.24 times higher risk and over 75-year-olds even around four times higher risk of hospitalization than younger patients. Additional comorbidities also influenced the course of the disease significantly. “Patients with cardiovascular diseases, chronic kidney diseases or lung diseases such as ILD or COPD were particularly often affected by severe disease,” said the researchers. In contrast, no increased risk of hospitalization could be found in those with asthma.

Additional risk factors in rheumatism

“In addition, there were also risk factors that were specifically related to an underlying rheumatic disease and its therapy,” emphasizes Dr. Rulers. As it turned out, rheumatism sufferers in particular had an increased risk of severe COVID-19 sales who took more than five milligrams of glucocorticoids daily. These drugs act on the immune system and increased the risk of severe COVID-19 courses in the cohort by a factor of 3.67. In addition, the risk of COVID-19 hospitalization was twice as high for those affected by rheumatism, whose current disease activity was rated as moderate to high.

Recommendation for rheumatism sufferers

“The connection between increased inflammatory rheumatic disease activity and a severe COVID-19 course is documented here for the first time,” emphasizes Professor Dr. med. Christof Specker, rheumatologist at the Essen-Mitte Clinic and head of the “Ad hoc Commission COVID-19 Register”. From the evaluation of the register data, the researchers derive the following urgent recommendations: “During the pandemic, it is important to ensure the best possible drug control of the underlying rheumatic disease. Wherever possible, the long-term administration of high-dose glucocorticoids should be avoided. “

As an alternative to glucocorticoids, Dr. Specker started a treatment with biologicals. They can be used to effectively control disease activity while reducing the glucocorticoid dose. The register database will be continued and updated monthly. (vb)

Author and source information

This text complies with the requirements of specialist medical literature, medical guidelines and current studies and has been checked by medical professionals.

Author:

Diploma-Editor (FH) Volker Blasek

Swell:

  • Hasseli R, Mueller-Ladner U, Hoyer BF, et al Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases RMD Open 2021, rmdopen.bmj.com
  • German Society for Rheumatology eV: COVID19 rheumatism register (accessed: 22.01.21), dgrh.de
  • German Society for Rheumatology eV: Risk factors for severe COVID-19 courses in patients with rheumatism (published: 21.09.2021), dgrh.de

Important NOTE:
This article is for general guidance only and is not intended to be used for self-diagnosis or self-treatment. He can not substitute a visit at the doctor.

.